A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

A Study of IMO-2125 in Combination with Ipilimumab vs Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)

Trial Category:
Melanoma
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members